Dengl, Stefan
Mayer, Klaus
Bormann, Felix
Duerr, Harald
Hoffmann, Eike
Nussbaum, Bianca
Tischler, Michael
Wagner, Martina
Kuglstatter, Andreas
Leibrock, Lea
Buldun, Can
Georges, Guy
Brinkmann, Ulrich http://orcid.org/0000-0002-5558-0212
Article History
Received: 8 May 2020
Accepted: 20 August 2020
First Online: 2 October 2020
Competing interests
: All authors are employed by Roche, Roche is interested in antibody engineering, therapeutic application of antibody derivatives, and targeted therapies. S.D., K.M., F.B., H.D., E.H., G.G., and U.B. are co-inventors of patent applications related to FORCE technologies. U.B., G.G., F.B., C.B., and S.D. own Roche stock (non-voting certificates).